Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition
Cantargia AB holds a large number of granted patents related to IL1RAP as a target for antibody treatment of cancer. One of Cantargia’s European patents for treatment of solid tumors, EP 3020730 B1, was opposed by a third party in 2019. Following a hearing at the European Patent Office (EPO), the Opposition Division confirmed the validity of this European patent and rejected the opposition. Cantargia’s extensive patent protection for IL1RAP-targeting therapy is thus fully maintained with unchanged claim scope.Cantargia has extensive patent protection for IL1RAP-targeted antibody therapy and
Kiiltonians regularly visit Pihla Group’s door factory, helping optimise adhesive-related processes and testing samples in climate chambers. The door factory’s production quality has improved even further since Kiilto’s service was introduced.Pihla Group is a window and door manufacturing company that is part of Inwido AB, the largest window and door manufacturer in Europe. Pihla Group’s Ruovesi door factory in Finland has relied on Kiilto adhesives for a long time. Over the last couple of years, the companies have further deepened their partnership.
“We have switched to using a service
